Business
Rafarma Pharmaceuticals, Inc. Receives General License for Pharmaceutical Products and has Started to Manufacture 3 New Products
Rafarma Pharmaceuticals, Inc. Receives General License for Pharmaceutical Products and has Started to Manufacture 3 New Products.
About this update from Rafarma Pharmaceuticals, Inc. (wy)
[{"type":"text","content":"\n\n\n\n\n\n\n\nRafarma Pharmaceuticals, Inc. Receives General License for Pharmaceutical Products and has Started to Manufacture 3 New Products\n\n\n/* Style Definitions */\nspan.prnews_span\n{\nfont-size:8pt;\nfont-family:\"Arial\";\ncolor:black;\n}\na.prnews_a\n{\ncolor:blue;\n}\nli.prnews_li\n{\nfont-size:8pt;\nfont-family:\"Arial\";\ncolor:black;\n}\np.prnews_p\n{\nfont-size:0.62em;\nfont-family:\"Arial\";\ncolor:black;\nmargin:\"0in\";\n}\n\n\n\n\n\n\n\n\n\n\nRafarma Pharmaceuticals, Inc. Receives General License for Pharmaceutical Products and has Started to Manufacture 3 New Products\n\nPR Newswire\n\nSANDY, Utah, Feb. 4, 2013\n\n\n\n\n\n\n\nSANDY, Utah, Feb. 4, 2013 /PRNewswire/ -- Rafarma Pharmaceuticals, Inc. (the \"Company\") OTC symbol (RAFA) announced that it has received the general license for pharmaceutical products and has started the manufacturing of 3 new products. The general license was one of the final steps required to open the new plant in Terbuniy. The Company is now in operation and is expected to rapidly increase to 100% capacity of the Terbiniy facility with the addition of government contracts provided by being 1 of 4 National Strategic Pharmaceutical Suppliers to the Russian Federation.\n\n\nThe new products are Sodium Para-Aminosalicilate, Ibuprofen, and Betagistin. Sodium Para-Aminosalicilate is a tablet with a time release cover. The current dosage manufactured is 1000 mg and is designed to be of use against various forms of tuberculosis. Sodium Para-Aminosalicilate can also be used in conjunction with other anti-tuberculosis medications. The Ibuprofen manufactured is Rectal Suppositories for children and the currently manufactured dosage is 60 mg. Betagistin Tablets are manufactured in dosages of 8 mg, 16 mg and 24 mg. The product is used to treat Manier Syndrome which is characterized by drowsiness, nausea, reduction in hearing abilities and noise in the ears. It is also used as treatment of vestibular vertigo.\n\n\nJulia Andrushkova, a company spokesperson, was quoted as saying: \"Receiving the general license for pharmaceutical products has been a major step to success for the many people involved, and for the Company in general.\"\n\n\nSafe Harbor Statement Matters discussed in this press release contain forward-looking statements within the mea...